Sertraline vs. Venlafaxine XR

Major Depressive Disorder Clinical Trial

Official title:

A Multi-center, Randomized, Double-blind, Parallel-group Study of Sertraline vs. Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00179283
• Other study ID #: Sert-Ven
• Status: Completed
• Phase: Phase 3
• First received: September 13, 2005
• Last updated: June 1, 2015
• Start date: April 2002
• Est. completion date: April 2003

Study information

• Verified date: June 2015
• Source: Vanderbilt University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, active control, 8-week, flexible dose study of sertraline vs. venlafaxine Extended Release in the acute treatment of Major Depression in male and female outpatient sites that will recruit 15-20 patients each. Subjects will be randomized in a 1:1 ratio to receive either sertraline or venlafaxine XR based on a computer-generated randomized list.

Description:

This is a randomized, double-blind, active control, 8-week, flexible dose study of sertraline vs. venlafaxine XR in the acute treatment of Major Depression in male and female outpatient sites that will recruit 15-20 patients each. Subjects will be randomized in a 1:1 ratio to receive either sertraline or venlafaxine XR based on a computer-generated randomized list.

The primary objectives of the study are: to assess the comparative safety and tolerability of sertraline and venlafaxine XR and to assess number and severity of discontinuation symptoms and time to termination of taper at the end of acute treatment with sertraline vs. venlafaxine XR.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Single or Recurrent Episode of MDD without psychotic features

• Additional diagnoses will be permitted only if they are identified as secondary diagnoses

• 18 or above on 17-item Ham-D with item 1 (depressed mood) score of 2 or above

Exclusion Criteria:

• Current or past diagnosis of Bipolar Disorder

• Any history or current psychotic disorder

• Current psychotic symptoms, including current delusional depression

• Current diagnosis of delirium or dementia

• Alcohol or drug abuse or dependence in last 6 months or currently

• Schizoid, Schizotypal, or Borderline Personality Disorder

• Non-response to sertraline at least 150mg for 4 weeks or more, venlafaxine XR at least 225mg for 4 weeks or more, or non-response to 2 antidepressants in the current episode

• Use of any antidepressant within 2 weeks of baseline (4 weeks for fluoxetine)

• Use of herbal and/or homeopathic remedies concomitantly or within 2 weeks of baseline excluding vitamins and mineral supplements

• Use within 1 week of baseline or concomitant use of any psychotropics with the exception zolpidem or zopiclone PRN for sleep

• Use within 4 weeks of baseline of benzodiazepines taken on a regular, daily basis (PRN use is acceptable as long as none in week leading up to randomization)

• Score of 3 or 4 on the suicide item, item 3 of the Ham-D scale at screen or baseline visit

• Participation in any other studies concomitantly or within 90 days prior to entry into this study

• Treatment with monoamine oxidase inhibitors within 14 days of baseline

• Treatment of electroconvulsive therapy within 30 days of baseline

• Previous history or intolerance or hypersensitivity and/or venlafaxine XR

• Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol

• Presence of serious and/or unstable medical condition

• Abnormal laboratory results

• Positive pregnancy test and/or nursing women or fertile women not practicing an effective method of birth control

• History seizure disorder-excluding febrile seizures of childhood

• Any other condition which in the investigator's judgement might increase the risk to the subject or decrease the chance of obtaining satisfactory data

• Mental condition rendering the subject unable to understand the procedures

• Unable and/or unlikely to comprehend and/or follow the protocol

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• sertraline

• venlafaxine XR

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ham-D (Hamilton Depression Rating Scale for Depression) 17-item
Primary	Clinical Global Impression - Severity Scale
Primary	Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
Primary	Treatment Emergent Symptom Scale-Revised (TESS-R)
Primary	Brief Symptom Inventory (BSI)
Secondary	NEO-5 factor Inventory (NEO-FFI)
Secondary	Anxiety Sensitivity Inventory (ASI)
Secondary	Mood Disorder Questionnaire (MDQ)
Secondary	Ham-A (Hamilton Rating Scale for Anxiety)
Secondary	Arizona Sexual Functioning Inventory (A-SEX)
Secondary	Atypical Features Inventory